How an emerging drug class dampens harmful immune reactions

An intranasal formulation of psychedelic 5-MeO-DMT (BPL-003) has completed a Phase 1 study of safety, tolerability and pharmacokinetics. BPL-003's effects were felt within minutes and resolved within 90 minutes. Drug now progressing into trial of people with treatment-resistant depression.

The Most Common Pain Relief Drug in The World Induces Risky Behavior, Study Shows

Diabetes drug semaglutide is surging in popularity. Is it safe?